SCHEMBL4845470

SCHEMBL4845470

CCOC(=O)C1CCCN(C(=O)OC(C)(C)C)N1C(=O)OC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 2/20 0.45
CTSK P43235 1/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
ALDH1A1 P00352 6/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 2/20 0.41
HSD17B10 Q99714 3/20 0.40
KDM4E B2RXH2 4/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HPGD P15428 3/20 0.37
GLA P06280 2/20 0.37
GAA P10253 1/20 0.37
LMNA P02545 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
RECQL P46063 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18562636 0.90 FKBP1A (0.42) FKBP1ACTSKMEN1KMT2AALDH1A1
SCHEMBL15443470 0.90 CTSK (0.42) FKBP1ACTSKMEN1KMT2AALDH1A1
SCHEMBL18562067 0.90 CTSK (0.42) FKBP1ACTSKMEN1KMT2AALDH1A1
SCHEMBL20858218 0.86 CTSK (0.41) FKBP1ACTSKMEN1KMT2AALDH1A1
SCHEMBL20858143 0.86 FKBP1A (0.39) FKBP1ACTSKMEN1KMT2AALDH1A1
SCHEMBL15447605 0.85 CTSK (0.43) FKBP1ACTSKMEN1KMT2AALDH1A1
SCHEMBL19479525 0.85 CTSK (0.43) FKBP1ACTSKMEN1KMT2AALDH1A1
SCHEMBL1401256 0.82 FKBP1A (0.58) FKBP1AMEN1KMT2AALDH1A1TSHR
SCHEMBL8223617 0.82 FKBP1A (0.58) FKBP1AMEN1KMT2AALDH1A1TSHR
SCHEMBL440340 0.82 FKBP1A (0.58) FKBP1AMEN1KMT2AALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342012-B2 Inhibitors of αLβ2 mediated cell adhesion MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-03-11 US disclosed
US-20050148602-A1 Inhibitors of alphaLbeta2 mediated cell adhesion TANABE SEIYAKU CO., LTD. 2005-07-07 US disclosed
US-6897225-B1 Inhibitors of αLβ2 mediated cell adhesion TANABE SEIYAKU CO., LTD. (JP) 2005-05-24 US disclosed
EP-1307455-B1 INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION TANABE SEIYAKU CO (JP) 2005-04-06 EP disclosed
EP-1307455-A2 INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION TANABE SEIYAKU CO., LTD. (JP) 2003-05-07 EP disclosed
WO-2001030781-A2 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION TANABE SEIYAKU CO., LTD. (JP) 2001-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148602-A1 Inhibitors of alphaLbeta2 mediated cell adhesion ITGB2, ITGA2B, ITGB1 FKBP1A 4149/4885CTSK 3079/4885MEN1 2408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.